Coordinating enforcement across Russia and foreign jurisdictions in pharma: how to sequence asset freezes effectively. A practical guide. Make an enquiry.
Pharmaceutical creditors pursuing Russian debtors rarely encounter a single-jurisdiction problem. In practice, the debtor's assets — manufacturing licences, distribution contracts, trade receivables, real property, and intellectual property registrations — are spread across Russia and one or more foreign jurisdictions, often including EAEU member states such as Kazakhstan or Belarus, and occasionally EU jurisdictions where the parent entity or its IP holdings are registered. Coordinating enforcement across Russia and foreign jurisdictions in the pharmaceuticals sector accordingly demands a sequenced, multi-front strategy: the order in which proceedings are commenced, and the timing of interim measures, will determine whether assets are preserved or dissipated before recovery becomes possible. Foreign creditors who approach Russian law pharmaceuticals enforcement as a linear process — win a judgment, then enforce it — routinely discover that the asset base has shifted during the time that approach takes to complete.
Before initiating any enforcement action, a creditor acting across jurisdictions in the pharmaceuticals sector should assemble the following:
This preparatory step is not procedurally mandated by Russian civil procedure, but in practice it determines the sequencing decisions that follow. Creditors who reach Step 2 without a consolidated asset picture frequently find themselves applying for interim relief against a partial asset set — and missing the assets that matter most.
If you are a pharmaceutical creditor mapping Russian and cross-border asset exposure before commencing proceedings, make an enquiry: info@vetrovpartners.com |
The first operational step in coordinating enforcement across Russia is a systematic jurisdictional triage. In the pharmaceuticals sector, this has a distinctive character: the debtor's economically significant assets are often intangible. A Russian pharmaceutical distributor or manufacturer will typically hold value in its Rospatent-registered trade marks and related IP licences, its pharmaceutical product registration certificates (issued by the Ministry of Health under Russian regulatory law), and its long-term distribution contracts with domestic retail chains or state procurement counterparties.
These assets are not uniformly attachable through the same procedural route. Trade marks registered with Rospatent can be the subject of interim injunctive relief in Russian state courts; product registration certificates, by contrast, are administrative authorisations personal to the holder and do not transfer on enforcement — meaning that a creditor who secures title to a debtor's manufacturing assets through insolvency or execution proceedings may nonetheless find that the underlying regulatory permissions do not follow. This is a sector-specific constraint that distinguishes pharmaceutical enforcement from, say, enforcement against a logistics company or a trading entity.
For foreign-registered assets — where the debtor holds participatory interests in EU entities, maintains bank accounts in EAEU member states, or has IP registrations under the Madrid System — the asset map must extend to each jurisdiction, with local counsel confirming the local attachment mechanism, the applicable limitation rule, and whether recognition of a Russian judgment or arbitral award is available in that forum as a matter of current court practice.
The Asset Tracing & Recovery practice at Vetrov & Partners conducts consolidated cross-border asset mapping as a discrete engagement, prior to and independent of litigation strategy.
Sequencing is the central strategic question in coordinating enforcement across Russia and foreign jurisdictions in the pharmaceuticals sector. The answer depends on three variables: where the most valuable attachable assets are located, which forum offers the fastest interim relief, and which judgment or award will be most readily recognised in the other jurisdictions involved.
For most foreign pharmaceutical creditors, the claim will be grounded in a commercial contract governed by Russian law and containing either a Russian state court jurisdiction clause or an arbitration clause referencing MKAS (the International Commercial Arbitration Court at the Chamber of Commerce and Industry) or a foreign institution such as the ICC or LCIA. Where a valid arbitration agreement exists, commencing at the agreed arbitral forum typically preserves the broadest enforcement options: an ICC or LCIA award can be recognised in Russia under the New York Convention, while a MKAS award is directly enforceable in Russian arbitrazh courts without the recognition step. The creditor should, however, not assume that commencing arbitration alone preserves Russian assets during the proceedings — Russian courts do not automatically grant asset-preservation orders in support of foreign arbitration, and a separate application to the competent Russian arbitrazh court for interim measures may be required in parallel.
Where the contractual basis is weaker, or where the debtor has commenced its own proceedings in Russia (for example, applying for voluntary insolvency), the timeline shifts materially. Under Russian insolvency legislation, a foreign creditor who has not registered its claim in the creditors' register within the prescribed deadline will lose priority in the distribution of the insolvent estate — a risk that frequently surprises creditors accustomed to English or German insolvency timetables. Timelines for creditor registration in Russian insolvency proceedings are short, and the consequences of missing them are irreversible in the sense that late creditors are subordinated in the ranking.
Note: Where a Russian debtor entity has filed for insolvency or where there are reasonable grounds to suspect an imminent filing, the creditor's first action must be to register the claim in the insolvency proceedings — not to commence separate enforcement proceedings, which are stayed by operation of Russian insolvency law. Failure to register within the statutory window results in subordination in the creditor ranking. Counsel familiar with the interaction between Russian insolvency legislation and cross-border enforcement should be instructed immediately.
For more on the interaction between Russian insolvency proceedings and coordinated cross-border recovery, see Court practice shifts on coordinating enforcement and the firm's broader analysis at Coordinating enforcement across Russia and foreign jurisdictions.
A Russian asset freeze — formally an interim injunction (обеспечительная мера) in Russian civil procedural terms — is applied for before or at the time of commencing substantive proceedings in the relevant arbitrazh court. Russian courts have the jurisdiction to grant such measures against assets located in Russia, including bank account attachments, prohibitions on the disposal of real property registered in EGRN, and injunctions against the transfer of participatory interests in Russian legal entities. In the pharmaceuticals sector, courts can additionally be asked to freeze Rospatent-registered IP rights, though the procedural route and the evidentiary threshold for such applications merit careful attention.
The evidentiary threshold for obtaining a Russian interim order is broadly analogous to the balance-of-convenience test familiar to common law practitioners: the applicant must demonstrate a plausible claim and a real risk that enforcement will be frustrated if the measure is not granted. Russian courts apply this test in practice with varying degrees of rigour depending on the circuit and the composition of the panel. In Siberian and Ural district courts, the firm's experience is that well-evidenced applications accompanied by a clear asset schedule are processed more efficiently than applications framed in general terms.
In parallel, where the debtor holds assets in EAEU member states, the Minsk Convention on legal assistance provides a treaty framework for mutual recognition and enforcement of judicial decisions among EAEU members — a mechanism that is practically faster than the New York Convention route for awards and substantially faster than bilateral treaty enforcement in most EU jurisdictions. For Kazakhstan and Belarus in particular, EAEU mechanisms mean that a Russian arbitrazh court order can be presented to local courts for recognition without re-litigating the merits.
For assets in EU jurisdictions, the position is more complex and requires local counsel input in the relevant state. The firm collaborates with trusted counsel in those jurisdictions for this purpose in accordance with its standard cross-border practice.
Step 4 — running parallel proceedings — is where the practical complexity of coordinating enforcement across Russia and foreign jurisdictions in the pharmaceuticals sector is most acutely felt. The core challenge is informational asymmetry and timing: an interim order obtained in Russia may not be recognised quickly enough in a foreign forum to prevent asset dissipation there, while proceedings commenced abroad may trigger a response from the debtor in Russia — including an insolvency filing — that complicates the Russian track.
Effective coordination requires at minimum: a single point of strategic control (lead counsel) who maintains real-time visibility across all active jurisdictions; a shared chronological enforcement map identifying the next material step in each jurisdiction and the deadline by which it must be taken; and clear protocols for information sharing between Russian and foreign counsel, including agreement on privilege and confidentiality arrangements across jurisdictions where these differ.
In the pharmaceuticals sector, an additional coordination layer arises where the debtor's licensing arrangements create dependencies between jurisdictions. A Russian entity that holds a licence from a foreign IP owner (for example, a European pharmaceutical originator) may have contractual provisions in the licence agreement that affect what happens to the Russian manufacturing or distribution rights on insolvency or enforcement — including rights of termination or step-in by the licensor. These provisions can materially affect the value of the asset pool available for creditor recovery and must be reviewed before enforcement strategy is finalised.
The Matters Hub records a range of cross-border enforcement matters handled by the firm, illustrating the sequencing approaches used across different sector and jurisdictional combinations.
For a confidential discussion about coordinating enforcement across Russia and one or more foreign jurisdictions in the pharmaceuticals sector, make an enquiry: info@vetrovpartners.com |
The final step in coordinating enforcement across Russia is translating a judgment, award, or insolvency distribution into funds that the foreign creditor can actually receive. This step is consistently underestimated in planning.
Where recovery is via a Russian arbitrazh court judgment or a MKAS award enforced in Russia, the procedural route runs through the Federal Bailiff Service (FSSP), which is responsible for executing money judgments against legal entities. The FSSP operates on a case management basis: once a writ of execution is issued, the bailiff has prescribed statutory timeframes within which to identify and attach debtor assets. In practice, timelines vary considerably depending on the responsiveness of Russian credit institutions and registrars to FSSP requests, and on whether the debtor has taken steps to conceal or transfer assets.
For pharmaceutical sector debtors specifically, recovery against product registration certificates and regulatory licences is not available through the standard FSSP execution route — these assets cannot be sold at auction to satisfy a money judgment. The recoverable asset pool is therefore effectively limited to bank accounts, real property, moveable property, participatory interests in legal entities, and registered IP rights. Understanding this limitation at the outset materially affects how the asset map is weighted and how interim measures are prioritised in Steps 1 through 3.
Repatriation of recovered funds from Russia is subject to Russian currency control legislation, which imposes procedural requirements on transfers to foreign accounts. In the current regulatory environment, foreign creditors should obtain specialist advice on the applicable currency control rules before finalising their recovery strategy, as the requirements and available routes may have changed since the creditor last engaged with the Russian market. The firm's Restructuring & Insolvency practice works closely with the Asset Tracing team on repatriation structuring.
Q: How long does it typically take to complete coordinated enforcement across Russia and a foreign jurisdiction in the pharmaceuticals sector?
A: Timelines vary substantially depending on the forum, the asset profile, and whether the debtor contests the proceedings. In a straightforward case involving a Russian arbitrazh court judgment on an uncontested commercial debt and simultaneous EAEU enforcement in Kazakhstan or Belarus, a creditor can realistically expect a first interim order within weeks of commencing proceedings in Russia, with final enforcement and distribution typically taking between twelve and twenty-four months from the date of filing. Where the matter involves foreign arbitration, an insolvency overlay, or contested IP rights, the timeline extends considerably. Creditors with exposure to the Russian pharmaceuticals sector should also account for the administrative timelines of the FSSP and the possible effect of currency control requirements on the repatriation of recovered sums.
Q: What documents does a foreign pharmaceutical creditor typically need to commence enforcement proceedings in Russia?
A: The core documents are: the underlying contract (distribution agreement, licensing agreement, or supply contract) with authenticated translation into Russian; the instrument evidencing the debt (invoice, payment claim, or demand notice); evidence of the creditor's legal standing (corporate documents of the foreign entity, apostilled or legalised); and, where the claim is based on a foreign arbitral award, a certified copy of the award and the arbitration agreement. Russian courts apply documentary requirements strictly — incomplete or improperly authenticated document sets will delay the acceptance of the claim. Where the contract contains a foreign law governing clause, a supporting expert opinion on foreign law content may also be required.
Q: What happens if the Russian debtor files for insolvency after enforcement proceedings have been commenced?
A: An insolvency filing by the Russian debtor suspends all active enforcement proceedings by operation of Russian insolvency legislation. Any writs of execution in the hands of the FSSP are returned; interim orders over assets may be discharged. The foreign creditor must register its claim in the insolvency creditors' register within the prescribed statutory deadline — which is short — in order to participate in the distribution. Existing enforcement steps already completed before the insolvency filing (including, in some cases, payments received from the debtor) may be subject to challenge as preferential transactions if they occurred within the look-back period. A foreign creditor facing this scenario should seek immediate specialist advice on both the registration deadline and the preferential transfer risk.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry